STROME MARK E 4

What Happened

• Mark E. Strome, reported as a 10% owner, made a purchase of 20,000 shares of Zivo Bioscience (ZIVO) on 2026-02-12 at $9.77 per share, totaling $195,400. The same Form 4 also reports an additional 2,000 shares as a derivative acquisition at $0.00. This filing describes the securities as owned directly by Strome Mezzanine Fund II, LP (SMF II), which acquired them under a Securities Purchase Agreement.

Key Details

• Transaction date(s): 2026-02-12.
• Purchase amounts/prices: 20,000 shares @ $9.77 ($195,400); 2,000 derivative shares @ $0.00.
• Ownership after transaction: The filing reports these securities are owned by SMF II; the Form 4 does not list a total post-transaction share count for Mark E. Strome personally. Footnotes state Strome Investment Management, LP and Strome Group, Inc., and Mark E. Strome may be deemed to share voting and investment power over SMF II’s holdings (see F1–F3).
• Footnotes: F1—securities owned directly by SMF II via Securities Purchase Agreement; F2—ownership/voting power shared among related entities and Mr. Strome; F3—filing language disclaiming admission of beneficial ownership under Section 16.
• Timeliness: The transaction occurred on 2026-02-12 and the Form 4 was filed 2026-02-17, which is later than the typical two-business-day reporting window for Section 16 insiders (the filing appears untimely).

Context

• This was a purchase (a buying transaction), which retail investors often view as a more informative signal than routine sales—but filings do not state motivation.
• The 2,000-share line is listed as a derivative acquisition at $0.00; the filing does not specify the derivative type (e.g., warrant, unit allocation, or other instrument), only that SMF II acquired the reported securities under the referenced purchase agreement.
• As a 10% owner acting through an investment fund (SMF II) rather than a personal, executive cash trade, this is institutional/affiliate buying reported under Section 16 rather than a direct personal brokerage purchase.